In combination with the previous safety targeting GC effect of CAR.B7H3-T cells both in vivo and in vitro, we might draw a conclusion that CAR.B7H3-T cells represent an emerging immunotherapy for the treatment of GC. This evidence concerns the gene CD276 and gastric cancer.